Phase 3 trial initiation in H1 2027 is the next catalyst. Monitor for regulatory feedback and any competitive developments in the POTS space. The Phase 2 data are early but address a high unmet need.
Drug in focus
REGN drug pipeline →baloncibart
● Neutral Named in this press release- Impact
- Phase
- Phase 2
- Time to market
- At least 4-6 years away, if successful. Both Phase 2 trials are complete but results have not been disclosed, and no Phase 3 trials have been registered. The drug would need positive Phase 2 data, Phase 3 trials, and FDA review before any potential approval.
- Next catalyst
- None dated
What to watchWatch for potential disclosure of Phase 2 topline results from either the POTS (PINNACLE) or sepsis (ESTELLA) trial, possibly at a future medical conference or in Regeneron's quarterly earnings materials. Positive results could support advancement to Phase 3, but given Regeneron's size and pipeline breadth, even a clear readout is unlikely to move the stock more than a few percent.
- ● Otarmeni 3/10 Approved (accelerated approval) · BLA filing 2026
- ▲ Cemdisiran 6/10 Filed/PDUFA (Phase 3 NIMBLE complete; NDA under FDA Priority Review)
- ▲ Dupixent 4/10 Approved (marketed since 2017; additional Phase 3 trials ongoing for label expansion)
- ● Evkeeza 4/10 Approved
- ● EYLEA HD 4/10 Approved
- 11 more · All REGN drugs, catalysts & trials →
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $955.47entry
- T+1 · 16h ago −0.32%α +1.59% · $952.40
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Regeneron announced positive Phase 2 PINNACLE trial results for baloncibart in POTS, showing a single 450 mg dose reduced heart rate upon standing and improved symptoms through four weeks. A potentially pivotal Phase 3 trial is planned for the first half of 2027. No FDA-approved treatments currently exist for POTS, which affects 500,000 to several million people in the U.S.
Key Facts
- Phase 2 PINNACLE trial evaluated single subcutaneous doses of baloncibart 150 mg (n=27) or 450 mg (n=28) vs placebo (n=27) in POTS patients.
- Baloncibart 450 mg reduced DeltaHR vs placebo at day 8 with LS mean difference of -11.4 bpm (nominal p=0.0007) and at day 29 with -7.4 bpm (nominal p=0.0124).
- Baloncibart 450 mg improved orthostatic symptoms, physical functioning, and activities of daily living vs placebo at day 29 per LWPQ.
- No FDA-approved treatments exist for POTS; potentially pivotal Phase 3 trial planned for first half of 2027.
- Single doses up to 450 mg were generally well tolerated; TEAEs mostly mild/moderate, no TEAE led to discontinuation.
Financial Impact
No financial figures stated; POTS affects 500K to several million U.S. patients with no approved therapies, representing a large potential market for Regeneron ($99.2B market cap).
Risk Factors
- Phase 3 trial may fail to replicate Phase 2 results; safety and efficacy not yet evaluated by any regulatory authority.
- POTS diagnosis and market size estimates are uncertain; commercial adoption depends on regulatory approval and reimbursement.
- Competing therapies may emerge before baloncibart reaches market.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3402308 |
Track record
53 reports on REGN
11 of 17 bullish or bearish reports moved the stock their way by T+20. Best: +31.76% at T+20 after the Oct 6, 2026 report. 17 of 20 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $951.23 Now $952.40 +0.12% settles Dec 16
- Nov 16, 2026today 144 Neutral 2/10 Entry $948.00 Now $952.40 +0.46% settles Dec 16
- Nov 12, 20264d ago Press Release Bullish 5/10 Viewing Entry $955.47 Now $952.40 −0.32% settles Dec 14
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 5, 202611d ago Insider Cluster Neutral 3/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 4, 202612d ago 144 Neutral 1/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers